Breaks Categories: News

TuesdayAug 27, 2024 2:24 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is announcing receipt of the first results from human pilot study #2, GLP-1-H24-2. According to the announcement, the company’s DehydraTECH(R)-processed Rybelsus(R) evidenced a trend toward higher overall absorption under fed conditions compared to Rybelsus(R) that was not processed with DehydraTECH. The DehydraTECH-processed Rybelsus(R) evidenced higher semaglutide levels in 17 of the 19 blood draws taken until the 24-hour completion of the study, averaging 18.8% higher semaglutide levels over the course of the study compared to Rybelsus(R) alone. However, the announcement noted that the differences were variable and not…

Continue Reading

ThursdayAug 22, 2024 1:01 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is reporting on 8-week body weight results from its ongoing animal study WEIGHT-A24-1. According to the company, this is the only study carried out anywhere in the world today to evaluate the relative performance of liraglutide processed with DehydraTECH. The results show that DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide. In humans, semaglutide has been shown in other studies to be more than twice as effective at promoting weight loss as liraglutide. Thus, the announcement noted that the continued outperformance of DehydraTECH-liraglutide compared to DehydraTECH-semaglutide is of particular interest. Additionally, the…

Continue Reading

ThursdayAug 22, 2024 10:22 am

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Subsidiary Secures Motor Carrier Authority, DOT Licenses

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced that its wholly owned subsidiary, LE Logistics, LLC (LE”), has officially secured the Motor Carrier Authority (“MC”) and U.S. Department of Transport (“DOT”) licenses. This development positions LE to immediately launch its freight division under the Golden Triangle Ventures umbrella and sets the stage for a stronger and more compliant operational foundation. In addition, it positions LE to start operations with its initial fleet of assets under a brand-new, clean operating license. The licenses also prime LE to execute its strategy of operating a larger fleet of assets, driving…

Continue Reading

WednesdayAug 21, 2024 12:39 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The results showed that DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A and B) were the top performers in the study at day 56, reducing blood sugar levels by 2.50%, 1.90% and 1.53% respectively. These results appear to support Lexaria’s belief that DehydraTECH-CBD may have utility, particularly if used together with a GLP-1 drug, in diabetic control. Additionally, select DehydraTECH-CBD…

Continue Reading

TuesdayAug 20, 2024 11:11 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical studies confirms INM-901, a proprietary small molecule drug candidate, as an oral formulation that will be utilized in the company’s development programs for Alzheimer’s disease. The data shows that the INM-901 formulation can be administered orally and maintains similar drug exposure and therapeutic levels as intraperitoneal (“IP”) delivery over a 24-hour period in the brain. The announcement noted that the oral delivery method offers potential advantages such as lower treatment delivery costs. “We are…

Continue Reading

MondayAug 19, 2024 11:45 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has released a report noting the positive findings from its applied research program. The program, which evaluated important mode of action facets of DehydraTECH(TM) processed with semaglutide, the glucagon-peptide 1 (“GLP-1”) drug, was conducted with the National Research Council of Canada ("NRC"). According to the company, the program was designed to examine the molecular properties of DehydraTECH-processed pure semaglutide in comparison to the commercially available semaglutide formulation Rybelsus(R). The program used simulated gastric fluid in order to mimic conditions in the human gut. Several testing methods were used, including…

Continue Reading

ThursdayAug 15, 2024 1:28 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) to Eliminate $450,000 of Convertible Debt by the End of Q3

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a holding company focused on the cannabis and agricultural technology sectors, today announced that all convertible debt on its balance sheet amounting to $450,000 will be eliminated by the end of the third quarter. “Our goal is to build a strong company focusing on revenue and, most importantly, enhanced shareholder value. We want our shareholders to invest with confidence, knowing they will not have to worry about any debt conversion hindering the value of their shares,” said Gabriel Diaz, CEO of MedCana. To view the full article, visit https://cnw.fm/RcoTF About Software Effective Solutions…

Continue Reading

ThursdayAug 15, 2024 12:10 pm

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Saxon Capital Group Partner to Bring ‘Groundbreaking’ Solar Glass Technology to Destino Ranch

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership with Saxon Capital Group Inc. (OTC: SCGX). As part of the partnership, SCGX will utilize and integrate its revolutionary Energy Glass Solar(TM) technology across the entirety of GTVH’s highly anticipated Destino Ranch project. Energy Glass Solar(TM) is a patented, optically clear photovoltaic window system that generates continuous electricity from sunlight, diffused, and ambient light. It is an ideal solution for Destino Ranch, offering numerous advantages. “We are thrilled to partner with Saxon Capital Group to bring their groundbreaking solar glass technology to Destino Ranch. This partnership…

Continue Reading

ThursdayAug 01, 2024 2:00 pm

CannabisNewsBreaks – 420 Expo Engages IBN, CNW to Drive Visibility to High-Interest Target Audiences

420 Expo, New Jersey’s first-ever BYOC (Bring Your Own Cannabis) consumer expo, has once again selected CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of the 60+ brands within the InvestorBrandNetwork (“IBN”), to serve as a media sponsor and the Official Newswire for the convention. Presented by Wakit Grinders, the event is scheduled for September 13-15, 2024, at the New Jersey Convention & Exposition Center in Edison, New Jersey. As one of the premier cannabis events in the United States, the Expo is expected to host 100+ vendors in the 100,000-square-foot venue with an estimated incredible…

Continue Reading

TuesdayJul 30, 2024 11:44 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot study. The company reported that results from the study confirm improvements in cognitive function, memory and locomotor activity and show statistical significance in certain behavioral assessments.According to the announcement, InMed is moving forward with additional molecular analyses to better define the mechanisms of action and…

Continue Reading